Article
Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Sept 2020
Zeng Chunling, Zhu Li, Jia Xiaona, Pang Yuzhi, Li Zhang, Lu Xiaojing, Xie Feifei, Duan Lili, Wang Yuexiang
Abstract excerpt
BACKGROUND: The majority of GISTs express mutationally activated KIT. Imatinib and sunitinib are approved KIT-inhibiting therapies. Their efficacy is usually hampered by the acquired multiple secondary drug-resistance KIT mutations. The most problematic resistance subset is GISTs with acquisition of secondary mutations in the KIT activation loop. Here, we establish the spectrum of activity of dasatinib against a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.